Regeneron Pharmaceuticals (REGN) Amortization of Deferred Charges (2012 - 2013)

Regeneron Pharmaceuticals' (REGN) quarterly Amortization of Deferred Charges came in at $5.7 million in Q4 2013, down 2.89% year-on-year from $5.9 million in Q4 2012, and down 4.27% quarter-over-quarter from $6.0 million in Q3 2013.

Regeneron Pharmaceuticals (REGN) Amortization of Deferred Charges (2012 - 2013) Analysis & Trends

Regeneron Pharmaceuticals' Amortization of Deferred Charges history runs 2 years deep, the most recent figure standing at $5.7 million for Q4 2013.

  • On a quarterly basis, Amortization of Deferred Charges fell 2.89% year-over-year to $5.7 million in Q4 2013; TTM through Dec 2013 was $23.1 million, a 0.59% increase from a year earlier, with the FY2013 full-year figure at $23.1 million, up 0.59% from the prior year.
  • Amortization of Deferred Charges retreated to $5.7 million in Q4 2013 per REGN's latest filing, from $6.0 million in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $6.0 million in Q3 2013 and bottomed at $5.5 million in Q2 2013.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn
7 Belite Bio 61.40 Bn 61.40 Bn -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn
9 Revolution Medicines 37.37 Bn 37.37 Bn -
10 Alnylam Pharmaceuticals 36.08 Bn 33.07 Bn 959.66 Mn

Historic Data

Download Data
DateValue
Dec 31, 2013 5.75 Mn
Dec 31, 2013 5.75 Mn
Sep 30, 2013 6.00 Mn
Sep 30, 2013 6.00 Mn
Jun 30, 2013 5.53 Mn
Jun 30, 2013 5.53 Mn
Mar 31, 2013 5.78 Mn
Mar 31, 2013 5.78 Mn
Dec 31, 2012 5.92 Mn
Dec 31, 2012 5.92 Mn
Sep 30, 2012 5.82 Mn
Sep 30, 2012 5.82 Mn
Jun 30, 2012 5.65 Mn
Jun 30, 2012 5.65 Mn
Mar 31, 2012 5.54 Mn
Mar 31, 2012 5.54 Mn